Actualités et perspectives thérapeutiques du lupus systémique

Sibilia, Jean; Pasquali, Jean‐Louis

doi:10.1016/j.lpm.2007.11.011

Cited by 5 publications

(1 citation statement)

References 121 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The literature is replete with examples of new uses for old drugs. For example, among the few drugs that are available in the treatment of malaria, quinine is used to treat muscle cramps [3], and chloroquine (CQ) (preferably hydroxyl-chloroquine) is used for the management of rheumatoid arthritis and systemic lupus erythematosus [4]. Artemisinin is being investigated for the treatment of schistosomiasis and cancer [5,6].…”

Section: The Need For New Antimalarial Drugsmentioning

confidence: 99%

Anticancer agents against malaria: time to revisit?

Nzila

Okombo

Becker

et al. 2010

Trends in Parasitology

View full text Add to dashboard Cite

The emergence of artemisinin resistance could adversely impact the current strategy for malaria treatment; thus, new drugs are urgently needed. A possible approach to developing new antimalarials is to find new uses for old drugs. Some anticancer agents such as methotrexate and trimetrexate are active against malaria. However, they are commonly perceived to be toxic and thus not suitable for malaria treatment. In this opinion article, we examine how the toxicity of anticancer agents is just a matter of dose or ‘only dose makes the poison’, as coined in Paracelsus’ law. Thus, the opportunity exists to discover new antimalarials using the anticancer pharmacopoeia.

show abstract

Section: The Need For New Antimalarial Drugsmentioning

confidence: 99%

Anticancer agents against malaria: time to revisit?

Nzila

Okombo

Becker

et al. 2010

Trends in Parasitology

View full text Add to dashboard Cite

show abstract

Anticancer Drug Repositioning Against Tropical Diseases: The Example of Methotrexate in the Treatment of Malaria

Nzila

Chibale

2012

Drug Discovery in Africa

View full text Add to dashboard Cite

Association study of CRP gene in systemic sclerosis in European Caucasian population

et al. 2013

View full text Add to dashboard Cite

Opsonization and apoptotic cell elements are critical in systemic lupus erythematosus (SLE) and could act through the activation of the innate immunity. C-reactive protein (CRP) belongs to opsonins, and polymorphisms of CRP gene have been shown to be associated with SLE susceptibility. Accumulating evidences show that SLE and systemic sclerosis (SSc) share some genetic susceptibility factors. To determine whether polymorphisms of CRP confer susceptibility to SSc, four SNPs (rs1130864, rs1205, rs1800947 and rs1341665), chosen using Hapmap linkage disequilibrium data and published data, were genotyped in a cohort of 651 SSc patients (569 with antinuclear antibodies, 258 with anti-centromere and 153 with anti-topoisomerase I) and 442 controls. All individuals were of French Caucasian origin. The four polymorphisms were in Hardy-Weinberg equilibrium in the control population. Allelic and genotypic frequencies for these four polymorphisms were found to be similar in SSc patients and controls. Moreover, subphenotype analyses in particular for subgroups having antinuclear antibodies did not detect any difference between SSc patients and controls. These results obtained through a large cohort of European Caucasian SSc patients do not support the implication of CRP gene in the pathogenesis of SSc.

show abstract

Actualités et perspectives thérapeutiques du lupus systémique

Cited by 5 publications

References 121 publications

Anticancer agents against malaria: time to revisit?

Anticancer agents against malaria: time to revisit?

Anticancer Drug Repositioning Against Tropical Diseases: The Example of Methotrexate in the Treatment of Malaria

Association study of CRP gene in systemic sclerosis in European Caucasian population

Contact Info

Product

Resources

About